Cara Therapeutics Price to Free Cash Flow Ratio 2012-2024 | CARA

Cara Therapeutics price to free cash flow ratio from 2012 to 2024. Price to free cash flow ratio can be defined as

Cara Therapeutics Price to Free Cash Flow Ratio 2012-2024 | CARA

Cara Therapeutics price to free cash flow ratio from 2012 to 2024. Price to free cash flow ratio can be defined as
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$119.5B
Regeneron Pharmaceuticals (REGN)$114.6B
Gilead Sciences (GILD)$103.4B
Bristol Myers Squibb (BMY)$101.6B
CSL (CSLLY)$97.4B
GSK (GSK)$84.8B
Alnylam Pharmaceuticals (ALNY)$35.2B
Argenex SE (ARGX)$31.4B
Biogen (BIIB)$28.2B
BioNTech SE (BNTX)$28B
Moderna (MRNA)$24.6B
Illumina (ILMN)$21.1B
BeiGene (BGNE)$20.7B
Genmab (GMAB)$16B
BioMarin Pharmaceutical (BMRN)$13.3B
Exact Sciences (EXAS)$12.6B
Incyte (INCY)$12.5B
Insmed (INSM)$12.5B
Vaxcyte (PCVX)$12.4B
Bio-Techne Corp (TECH)$12.4B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.3B
Bio-Rad Laboratories (BIO.B)$9.1B
Ascendis Pharma (ASND)$8.6B
Roivant Sciences (ROIV)$8.6B
Legend Biotech (LEGN)$8.5B
Repligen (RGEN)$8.2B
Intra-Cellular Therapies (ITCI)$7.7B
Exelixis (EXEL)$7.5B